VEGFA and Fabry disease: No statistically relevant influence of co-medication on VEGFα levels could be found, although there was a trend toward lower VEGFα serum concentrations in patients with Fabry’s disease under ERT compared with those in the small group of untreated patients with Fabry’s disease.